TOH edition: Wednesday, 28 October 2026 · Health & Medicine
More Time Before Breast Cancer Advances: A New Combination Improved Disease Control in a HER2-Positive Trial
Reported by note.com
Publisher date:
A reported Phase III trial offers evidence of a potential new way to delay progression of HER2-positive metastatic breast cancer. According to the supplied account, anbenitamab plus HB1801 reduced the hazard of disease progression or death by 54% compared with trastuzumab, pertuzumab and docetaxel, without establishing longer overall survival.
Better disease control could expand treatment possibilities for people with advanced breast cancer, although this result does not establish a cure or superiority over newer treatment options.
Read the original report at note.com (opens in a new tab) →
Read the full front page of Wednesday, 28 October 2026 →
Get tomorrow's front page
Five reasons to believe in progress, delivered once a day.